• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: IRIDEX Corporation filed SEC Form 8-K: Leadership Update

    11/25/24 7:16:57 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $IRIX alert in real time by email
    8-K/A
    0001006045trueNASDAQ00010060452024-11-072024-11-07

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K/A

    (Amendment No. 1)

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

     

    November 7, 2024

     

    (Date of Report (date of earliest event reported))

     

    IRIDEX CORPORATION

    (Exact name of registrant as specified in its charter)

     

    Delaware

    000-27598

    77-0210467

    (State or other jurisdiction of
    incorporation or organization)

    (Commission File Number)

    (I.R.S. Employer
    Identification Number)

    1212 Terra Bella Avenue
    Mountain View, California 94043

    (Address of principal executive offices, including zip code)

     

    (650) 940-4700

    (Registrant’s telephone number, including area code)

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    Securities registered pursuant to Section 12(b) of the Act:

     


     

    Title of Class

     

    Trading

    Symbol

     

    Name of Exchange on Which Registered

    Common Stock, par value $0.01 per share

     

    IRIX

     

    Nasdaq Capital Market

    Explanatory Note

    This Current Report on Form 8-K/A amends the Current Report on Form 8-K filed by IRIDEX Corporation, a Delaware Corporation (the “Company”) with the Securities and Exchange Commission on November 13, 2024 (the “Original Report”). The purpose of this Current Report on Form 8-K/A is (i) to correct David I. Bruce’s resignation date from the Company’s board of directors (the “Board”) and (ii) to provide a supplemental disclosure related to Mr. Bruce’s resignation.

    Except as set forth herein, no modifications have been made to information contained in the Original Report. Accordingly, this Form 8-K/A should be read in conjunction with the Original Report and other filings made by Iridex Corporation with the Securities and Exchange Commission.

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    David Bruce Resignation and Separation Agreement

     

    On October 1, 2024, Dave Bruce was terminated as the Company’s Chief Executive Officer and principal executive officer, effective immediately, and on November 22, 2024, Mr. Bruce resigned from the Board, effective immediately. Mr. Bruce’s decision to resign was not the result of any disagreement with the policies, procedures or practices of the Company. The Board thanks Mr. Bruce for his service to the Company.

     

    Pursuant to the terms of Mr. Bruce’s employment agreement, Mr. Bruce was eligible to receive certain severance benefits in connection with his termination, subject to his entry into a separation agreement with the Company. On November 11, 2024, Mr. Bruce and the Company entered into a separation and release agreement (the “Separation Agreement”) providing for certain benefits in exchange for a release of claims by Mr. Bruce and compliance with certain ongoing covenants, including:

     

    •
    a lump sum of $45,000, consisting of $20,000 to continue health insurance coverage pursuant to the Consolidated Omnibus Reconciliation Act (“COBRA”), which is approximately equivalent to 12 months of Mr. Bruce’s estimated COBRA premiums, and $25,000 for other intangibles.

     

    •
    100% of Mr. Bruce’s remaining 19,913 unvested restricted stock unit awards (the “Accelerated RSUs”) and 100% of the unvested options to purchase 40,431 of the Company’s common stock (the “Accelerated Options”), each granted on October 27, 2022, to accelerate and fully vest as of the date of the Separation Agreement.

     

    Mr. Bruce shall have twelve (12) months from October 4, 2024 (the “Separation Date”) to exercise any vested and unexercised options to purchase the Company’s common stock unless such options expire prior to the end of such twelve-month period. Except for the Accelerated Options and Accelerated RSUs, Mr. Bruce’s unvested options to purchase common stock and unvested restricted stock units ceased vesting and were forfeited on the Separation Date.

     

    Pursuant to the terms of the Separation Agreement, Mr. Bruce will remain bound by the confidentiality provisions and certain restrictive covenants included in his employment agreement.

     

    The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Separation Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Patrick Mercer Compensatory Arrangements and Change in Control Severance Agreement

     

    -2-


     

    On November 7, 2024, the Board adjusted the terms of Patrick Mercer’s compensation in connection with his role as CEO. Mr. Mercer will retain an annualized 2024 base salary of $360,000 and will be eligible to receive an annual target bonus of 65% of his 2024 annual base salary upon the achievement of certain performance objectives determined by the Company’s Compensation Committee and Board. In addition, Mr. Mercer entered into an amended and restated Change in Control Severance Agreement, in which Mr. Mercer would be entitled to a lump sum cash severance payment equal to 150% of his base salary then in effect, if terminated without cause (as defined therein) or in connection with a change in control (as defined in the Plan). The foregoing description of the Change in Control Severance Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Change in Control Severance Agreement, which is filed as Exhibit 10.2 to this Current Report on Form 8-K and incorporated herein by reference.

    -3-


     

     

     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    IRIDEX CORPORATION

    By:

    /s/ Patrick Mercer

    Patrick Mercer

    President and Chief Executive Officer

    Date: November 25, 2024

     

    -4-


    Get the next $IRIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IRIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Dizon Romeo R bought $2,145 worth of shares (1,500 units at $1.43), increasing direct ownership by 1% to 117,690 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    2/12/26 10:05:32 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Dizon Romeo R bought $1,460 worth of shares (1,000 units at $1.46), increasing direct ownership by 0.87% to 116,190 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    2/10/26 3:19:41 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Dizon Romeo R bought $3,450 worth of shares (2,500 units at $1.38), increasing direct ownership by 2% to 115,190 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    2/3/26 6:21:19 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $IRIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Iridex Announces Plans to Relocate Headquarters

    MOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its intent to relocate the Company's headquarters from Mountain View, California to San Jose, California. On January 26, 2026, the Company signed a non-binding letter of intent for a new lease (the "Lease"). The Company plans to move to the 31,000 square feet location and is expecting to generate savings of approximately $0.4 million in fiscal year 2026 and approximately $0.6 million in savings on an annualized b

    2/2/26 7:00:00 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025

    MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Results Total revenue is expected to be between $14.6 million and $14.8 million compared to $12.7 million in the prior year quarter, representing year-over-year growth between 15% and 17%Achieved positive cash flow in the fourth quarterSold 15,800 Cyclo G6® probes compared to 13

    1/12/26 7:00:00 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management

    MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of transscleral laser treatment using MicroPulse® technology (MicroPulse TLT) can safely and effectively further reduce intraocular pressure (IOP) in patients with glaucoma.1 The study, conducted at the University Eye Clinic Maastricht, aimed to assess the effectiveness, repeatability, and safety

    12/11/25 7:00:00 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $IRIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Iridex with a new price target

    Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $11.00 from $9.00 previously

    5/12/21 11:32:01 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Roth Capital reiterated coverage on IRIDEX with a new price target

    Roth Capital reiterated coverage of IRIDEX with a rating of Buy and set a new price target of $9.00 from $6.00 previously

    3/9/21 8:09:06 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Roth Capital reiterated coverage on Iridex with a new price target

    Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $9.00 from $6.00 previously

    3/3/21 12:29:03 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $IRIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Dizon Romeo R bought $2,145 worth of shares (1,500 units at $1.43), increasing direct ownership by 1% to 117,690 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    2/12/26 10:05:32 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Dizon Romeo R bought $1,460 worth of shares (1,000 units at $1.46), increasing direct ownership by 0.87% to 116,190 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    2/10/26 3:19:41 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Dizon Romeo R bought $3,450 worth of shares (2,500 units at $1.38), increasing direct ownership by 2% to 115,190 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    2/3/26 6:21:19 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $IRIX
    SEC Filings

    View All

    IRIDEX Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - IRIDEX CORP (0001006045) (Filer)

    1/12/26 9:11:03 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    IRIDEX Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - IRIDEX CORP (0001006045) (Filer)

    12/11/25 10:16:09 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by IRIDEX Corporation

    10-Q - IRIDEX CORP (0001006045) (Filer)

    11/12/25 4:25:55 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $IRIX
    Financials

    Live finance-specific insights

    View All

    Iridex Reports Third Quarter 2025 Financial Results

    MOUNTAIN VIEW, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 27, 2025. Third Quarter 2025 Financial Highlights Generated total revenue of $12.5 million, representing growth of 8% year-over-year compared to $11.6 million in the prior year quarterCyclo G6® product family revenue was $3.5 million, representing growth of 13% year-over-year compared to $3.1 million in the prior year quarter Sold 14,900 Cyclo G6 probes comp

    11/11/25 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Iridex to Report Third Quarter 2025 Financial Results on November 11, 2025

    MOUNTAIN VIEW, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the third quarter 2025 and provide a business update after the close of trading on Tuesday, November 11, 2025. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 from the US or +1-646-968-2525 internationally and providi

    10/28/25 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Iridex Reports Second Quarter 2025 Financial Results

    MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended June 28, 2025. Second Quarter 2025 Financial Highlights Generated total revenue of $13.6 million, representing growth of 7% year-over-year and 14% sequential growth versus the first quarter of 2025Cyclo G6® product family revenue was $3.3 million, essentially flat year-over-year Sold 13,100 Cyclo G6 probes compared to 15,100 in the prior year quarterSold 35 Cyclo G6

    8/12/25 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $IRIX
    Leadership Updates

    Live Leadership Updates

    View All

    Iridex Appoints Patrick Mercer as Chief Executive Officer

    MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company's Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company's Chief Operating Officer and President. David Bruce, the Company's prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer's appointment, Scott Shuda was appointed Executive Chairman of the Company's board of directors. M

    10/3/24 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

    MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse® Transscleral Laser Therapy (TLT) using Iridex' Cyclo G6® Laser and the MicroPulse P3® Delivery Device. This partnership establishes a large-scale enrollment platform to advance clinical research. David I. Bruce, President and CEO of Iridex, shared: "The first patient enrollment in this partnership with Imperial College Healthcare NHS Trust is the first step toward mu

    1/24/24 8:00:00 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Iridex Announces the Appointment of Beverly Huss to its Board of Directors

    MOUNTAIN VIEW, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Beverly Huss to its board of directors, effective, March 17, 2022. In connection with Ms. Huss' appointment to the board, the size of the board was increased from five to six members as of the Effective Date. "I am very pleased to welcome Beverly to our board of directors," said Scott Shuda, chairman of the board of Iridex. "Beverly's extensive management and board experience in the medical device industry and proven track record with non-invasive a

    3/21/22 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $IRIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by IRIDEX Corporation

    SC 13D - IRIDEX CORP (0001006045) (Subject)

    11/23/22 4:57:01 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D filed by IRIDEX Corporation

    SC 13D - IRIDEX CORP (0001006045) (Subject)

    9/20/22 2:06:59 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by IRIDEX Corporation (Amendment)

    SC 13G/A - IRIDEX CORP (0001006045) (Subject)

    2/10/22 8:17:17 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care